Japan Stock of the Day | Kabutaro & Friends

On October 21, 2026, the most talked-about Japanese stock online was Cuorips <4894>.
Background: Cuorips is a biotech company spun off from Osaka University that develops "ReHeart," a heart muscle sheet made from iPS cells. On the 21st, a patient who underwent surgery using ReHeart held a press conference, and it was reported that the patient was recovering well after surgery and was scheduled to be discharged on the 22nd. ReHeart received conditional and time-limited manufacturing and marketing approval in March 2026, and on September 29 the first transplant since it became covered by health insurance was performed at a hospital in Osaka City. Buying gathered on expectations that treatment of serious heart disease will expand, and the stock closed at 7,000 yen, up 810 yen (+13.09%) from the previous day. The high was 7,060 yen, and the stock is listed on the Growth Market. Trading volume was 450,500 shares, turnover was about 3 billion yen, and market capitalization was about 62.3 billion yen. Among iPS cell-related stocks, Healios also rose 8.5%.